Bharat Parenterals Limited BPLPHARMA NSE
Company Profile ↓Company Overview
Bharat Parenterals Limited (BPLPHARMA) is a publicly traded company listed on NSE with a market capitalization of ₹1,056.74 Cr. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 16.7% CAGR over the past five years.
Recent Developments
- Mar 2026 Revenue of ₹345.43 Cr (+1.5% YoY); net profit ₹-8.19 Cr.
- Trailing 12 Months Year-on-year growth — revenue +1.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 16.7%, profit CAGR -49.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 16.66% |
| 1 Year: | 1.48% |
Compounded Profit Growth
| 5 Years: | -49.93% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +21.23% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 16.7% over 5 years.
CONS
- Earnings shrank at -49.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 103.98 Cr | 116.00 Cr | 64.62 Cr | 65.19 Cr | 99.62 Cr |
| Cost of Revenue | 53.54 Cr | 68.85 Cr | 26.92 Cr | 32.31 Cr | 57.75 Cr |
| Gross Profit | 50.44 Cr | 47.15 Cr | 37.70 Cr | 32.88 Cr | 41.87 Cr |
| Operating Expenses | 56.73 Cr | 41.97 Cr | 45.44 Cr | 39.60 Cr | 51.02 Cr |
| Operating Income | -6.28 Cr | 5.18 Cr | -7.74 Cr | -6.71 Cr | -9.15 Cr |
| EBITDA | 4.16 Cr | 14.84 Cr | 4.36 Cr | 3.07 Cr | 3.10 Cr |
| Interest Expense | 3.94 Cr | 3.69 Cr | 3.11 Cr | 2.90 Cr | 2.85 Cr |
| Pretax Income | -8.30 Cr | 2.55 Cr | -7.31 Cr | -8.28 Cr | -8.37 Cr |
| Tax Provision | 1.14 Cr | 3.42 Cr | 1.29 Cr | 1.39 Cr | -21.19 L |
| Net Income | -4.73 Cr | 8.23 Cr | -7.24 Cr | -5.28 Cr | -4.80 Cr |
| Diluted EPS | - | - | - | - | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 217.56 Cr | 257.05 Cr | 340.38 Cr | 345.43 Cr |
| Cost of Revenue | - | 145.58 Cr | 168.53 Cr | 199.64 Cr | 191.40 Cr |
| Gross Profit | - | 71.99 Cr | 88.52 Cr | 140.74 Cr | 154.04 Cr |
| Operating Expenses | - | 56.26 Cr | 70.42 Cr | 173.36 Cr | 172.47 Cr |
| Operating Income | - | 15.73 Cr | 18.10 Cr | -32.62 Cr | -18.43 Cr |
| EBITDA | - | 31.62 Cr | 30.92 Cr | 14.32 Cr | 25.36 Cr |
| Interest Expense | - | 2.19 Cr | 3.18 Cr | 12.95 Cr | 12.53 Cr |
| Pretax Income | - | 23.55 Cr | 18.72 Cr | -33.95 Cr | -21.42 Cr |
| Tax Provision | - | 7.83 Cr | 8.21 Cr | 9.72 Cr | 5.88 Cr |
| Net Income | - | 16.44 Cr | 14.52 Cr | -12.63 Cr | -8.19 Cr |
| Diluted EPS | - | 28.40 | 24.94 | -66.64 | -39.62 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 350.34 Cr | 504.04 Cr | 648.53 Cr | 613.30 Cr |
| Current Assets | - | 184.28 Cr | 262.00 Cr | 355.52 Cr | 310.08 Cr |
| Cash & Equivalents | - | 7.85 Cr | 8.71 Cr | 56.00 L | 1.48 Cr |
| Inventory | - | 37.84 Cr | 61.47 Cr | 71.95 Cr | 84.72 Cr |
| Receivables | - | 112.41 Cr | 141.42 Cr | 171.74 Cr | 150.65 Cr |
| Total Liabilities | - | 132.44 Cr | 265.87 Cr | 309.53 Cr | 301.72 Cr |
| Current Liabilities | - | 119.80 Cr | 189.83 Cr | 219.30 Cr | 157.39 Cr |
| Long Term Debt | - | 10.92 Cr | 73.16 Cr | 75.87 Cr | 121.79 Cr |
| Total Debt | - | 49.74 Cr | 157.58 Cr | 180.20 Cr | 146.11 Cr |
| Total Equity | - | 182.80 Cr | 197.27 Cr | 330.67 Cr | 322.23 Cr |
| Shares Outstanding | - | 57.75 L | 58.20 L | 68.92 L | 68.92 L |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 21.66 Cr | -4.71 Cr | -27.25 Cr | 38.36 Cr |
| Investing Cash Flow | - | -77.82 Cr | -104.78 Cr | -137.38 Cr | 9.32 Cr |
| Financing Cash Flow | - | 60.60 Cr | 110.43 Cr | 156.37 Cr | -47.05 Cr |
| Capital Expenditure | - | -91.60 Cr | -104.30 Cr | -29.08 Cr | -39.93 Cr |
| Free Cash Flow | - | -69.94 Cr | -109.01 Cr | -56.33 Cr | -1.57 Cr |
| Net Change in Cash | - | 4.44 Cr | 93.81 L | -8.27 Cr | 63.68 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 33.1% | 34.4% | 41.3% | 44.6% |
| Operating Margin % | - | 7.2% | 7.0% | -9.6% | -5.3% |
| Net Margin % | - | 7.6% | 5.6% | -3.7% | -2.4% |
| ROE % | - | 9.0% | 7.4% | -3.8% | -2.5% |
| ROCE % | - | 6.8% | 5.8% | -7.6% | -4.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BPLPHARMA
Bharat Parenterals Ltd. (BPLPHARMA) Share Price Today, Quote, Latest Discussions, Interactive Chart and News - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE14d1NhRUNOdmFwR0Z6eFk4bVhzUExnUWROVnJMbVhodTU2bk8yU3hzNEFvUTJTMkhkckhNaDcyU1hsRktnTm5HV3NsQU5mY1J1QmlsNnpB?oc=5" target="_blank">Bharat Parenterals Ltd. (BPLPHARMA) Share Price Tod…
Bharat Parenterals Ltd. Statistics – NSE:BPLPHARMA - TradingView
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNVkFMOFB3d0RsYTdPelFzZFFNRjVreHdMaUlYOVZvQXl3OC1XTnMtOVBVdU9wLXJFU1lJclBXNzVBRkc3bUstajFrMjhBWldweng0MUlrQVl5NjNIU3VhTS01S2k3YkpaeDZQMUNQRUktYlUxVkcteGVLcnhrZ1VDS2JwLUxESmQ1TjBN?o…
BPLPHARMA Stock Price and Chart — NSE:BPLPHARMA - TradingView
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xdUljQWtzNDVnVWFxWDhVY0ZvYVJBZmI4eHM2TXNaWE5IVV9ySUM1eVdwT2pIZWZHSGdiLVpUZEQ4VjJQZVVtS201Q1JrNUFrWmVhaEJxWFg1eVZyTGFZ?oc=5" target="_blank">BPLPHARMA Stock Price and Chart — NSE:B…
Bharat Parenterals Ltd. (BPLPHARMA) Profile, Company FAQs & Facts, Industry, Sector, Employee Strength - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE5Nb0Vua2dhZjJ4ZjJEd2NZejA3LXZmYjZ3d3hPdUduUjRMclZ5S3QwaWpXMll2SG5uNXFYYWhZcHozaV9walZNc21IR3dxemdZZ1lTSkhpUjdtUndvUEE?oc=5" target="_blank">Bharat Parenterals Ltd. (BPLPHARMA) Prof…
Bharat Parenterals equity shares begin trading on NSE - scanx.trade
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOWHhobVIxQmpKdE5NQXdldmMtQXRfaHI1c0d2TVY0LXlvX2VmaGt1em5pb1QxMVBNbGdubXBQNzkzeVRvMzQxdTRTUTNYcHZVZ2RlLWZXYksxZFIxVXZhZ3VCRkp1RXE0MTdMc0pOV2IwQU82VE5kMDhlYk1CZi12N2VrVW1oWU5lckFZSz…
NGLFINE Stock Price and Chart — NSE:NGLFINE - TradingView
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE1LUUszaEotVmh3dmZzQVdickVmS3V5TTFJYW5MeTdlU0RGTmNwWWRlWndMZ3VnZ1Z3MTh3X1EwYUhiTFdfOHNHbGtDd0JZQ2hCZ1l1ZlAwZDgwSkR1?oc=5" target="_blank">NGLFINE Stock Price and Chart — NSE:NGLFINE…
BPLPHARMA — Frequently Asked Questions
What is the current share price of Bharat Parenterals Limited (BPLPHARMA)?
As of 2026-09-08 04:53 IST, Bharat Parenterals Limited (BPLPHARMA) trades at ₹1,533.30 on NSE. Its 52-week range is ₹1,264.80 to ₹1,541.20.
What is the market capitalisation of BPLPHARMA?
Bharat Parenterals Limited (BPLPHARMA) has a market capitalisation of ₹1,056.74 Cr on NSE.
What is the P/E ratio of BPLPHARMA?
BPLPHARMA trades at a trailing price-to-earnings (P/E) ratio of -38.70. Its price-to-book (P/B) ratio is 2.99.
What is the return on equity (ROE) of BPLPHARMA?
BPLPHARMA has a return on equity (ROE) of -2.54%. Its return on capital employed (ROCE) is -4.04%.
Is BPLPHARMA a good stock to buy?
This page provides a data-driven analysis of Bharat Parenterals Limited (BPLPHARMA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.